Abstract:Administration of cytotoxic drugs is accompanied by many serious side effects, with cardiac toxicity as one of the most dangerous. In clinical practice anthracyclines are the best known chemotherapeutic agents linked to cardiotoxicity, however there are a number of other anti-cancer drugs (cyclophosphamide, taxans, trastuzumab, 5-fluorouracil, imunomodulators etc) that may cause cardiac toxicity as well. Basic mechanism through which anthracylines cause cardiac damage is recognized, though many pathogenetic ways of their toxicity still remain to be elucidated. Administration of trastuzumab is also clearly associated with cardiotoxicity, however, depression of left ventricular ejection fraction (LVEF) caused by this agent (unlike anthacyclines) seems to be fully reversible. For monitoring cardiotoxicity we use several methods--biochemical examination, use of X-ray, radionuclides or ultrasound. The most commonly used method to identify patients with heart damage is echocardiography with clinical examination. When a cardiac damage (mostly congestive heart failure with low LVEF) occures, following treatment depends on clinical symptoms and LVEF. These patients are then treated according to common internal medecine recommendations. Several cardioprotective agents have been tested, among these dexarazoxane seems do show significant cardioprotective activity. Also liposomal encapsulation of anthacyclines may reduce heart damage, especially early cardiotoxicity. Cardiotoxicity of cytostatic agents is a very serious side effect of anti-cancer therapy, which may affect survival more than the malignancy itself. Therefore a concentrated effort should be expended to prevent cardiac damage or at least to its early identification and prompt treatment.

WASP-NET: Recent advances in fast EM CAD and optimization of waveguide components, feeds and aperture antennas

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

[Cardiotoxicity of drugs used in oncology]

A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Comments on the question of incestuous marriages in old Iran.

The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

Further evidence for GABA-ergic mechanisms in the action of benzodiazepines.

In vitro bone lipid synthesis in air and nitrogen.

Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?

Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells

Screening of renal artery stenosis: assessment with magnetic resonance angiography at 1.0 T.

Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death

Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury

Doxorubicin induced heart failure: Phenotype and molecular mechanisms